Signaling Pathways Identification Services
Despite significant advances in the diagnosis and treatment of leukemia in recent years, the underlying molecular mechanisms of this disease still need to be explored in greater depth. Understanding the signaling pathways involved in the pathogenesis of leukemia is helpful in developing drug targets. Alfa Cytology' characterization services can identify these pathways. We are dedicated to meeting clients' research needs regarding signaling pathways in leukemia, offering high-quality services, precise analytical results, and comprehensive solutions.
Introduction to Signaling Pathways in Leukemia
Leukemia is a malignancy of the blood system and there are many types. The cause of leukemia is unknown, but it is believed to be a combination of genetic and environmental factors. The pathogenesis of leukemia is related to the abnormal activation of several signaling pathways. In leukemia, Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR, and JAK/STAT pathways are activated due to upstream cytokine receptor mutations, chromosomal aberrations, and other genetic alterations. Treating leukemia with chemotherapy drugs is challenging due to the varying types of leukemia. Therefore, the development of targeted therapeutic drugs that address abnormal signaling pathways has become a focus in leukemia treatment.
Fig. 1. Scheme of the effector miRs and inhibitors in PI3K/Akt/mTOR pathway in different leukemias. (Bertacchini, J. et al., 2015)
Alfa Cytology provides leukemia signaling pathway identification, screening, and analysis services to support you in paying attention to the exploration of signaling pathways in leukemia, to find suitable targets and new treatment ideas for drug development. If you are concerned about the signaling pathways involved in leukemia pathogenesis, we provide the following signaling pathways:
- Ras/Raf/MEK/ERK
- PI3K/PTEN/AKT/mTOR
- Hedgehog
- JAK/STAT
- NF-κB
- NOTCH/MYC
- TGF-β
- WNT
Please let us know if you have any specific inquiries or if there is any particular aspect of signaling pathways in leukemia that you would like to explore further.
Service Process for Identifying Leukemia Signaling Pathways
Customized Models
We offer a range of leukemia cell lines, including AML, ALL, CML, and CLL, for studying leukemia signaling pathways.
Multiomics analysis
Based on multiomics analysis, we can identify enriched signaling pathways and select potential pathways that may be of interest to you.
Luciferase reporter gene detection
Activation or inhibition of signaling pathways was assessed by intracellular luciferase reporter genes.
Antibody array and protein profile detection
The protein changes in the signaling pathway were detected by antibody array and protein profile, and analyze whether they affect signaling pathways of interest or identify signaling pathways associated with leukemia pathogenesis.
Validation pathway
To investigate the effects of gene editing, RNA interference, or inhibitors to inhibit the signaling pathways on the proliferation and survival of leukemia cells, and to evaluate their potential as therapeutic targets.
Result report
We provide a complete analysis of the experimental process and results and deliver the results on time.
Advantages of Our Services
- Multiple types of leukemia models
- Mature single cell sequencing technology
- High throughput protein analysis technology
- Excellent omics analysis platform
- A team of experienced scientists in the field of leukemia research
- Tailor it to the specific needs of your project
Alfa Cytology offers comprehensive and highly specialized services that are fully customizable to meet the unique needs of our clients in the field of leukemia pathway identification. Our signaling pathway research services for leukemia pathogenesis can detect the activation or inhibition of signaling pathways during leukemia development, or explore new signaling pathways for you. If you are interested in or would like to learn more about our leukemia pathway identification services, please do not hesitate to contact us.
Reference
- Bertacchini, J.; et al. Targeting PI3K/AKT/mTOR network for treatment of leukemia. Cell. Mol. Life Sci. 2015, 72: 2337–2347.